Basit öğe kaydını göster

Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency

dc.contributor.authorKutlug, Seyhan
dc.contributor.authorKapakli, Hasan
dc.contributor.authorBaser, Dilek
dc.contributor.authorKasap, Nurhan
dc.contributor.authorAltintas, Derya Ufuk
dc.contributor.authorAL-SHAIBI, Ahmad
dc.contributor.authorAGREBI, Nourhen
dc.contributor.authorAYDOGMUS, Cigdem
dc.contributor.authorMETIN, Ayse
dc.contributor.authorAydogan, Metin
dc.contributor.authorUncuoglu, Aysen
dc.contributor.authorPatiroglu, Turkan
dc.contributor.authorYildiran, Alisan
dc.contributor.authorGuner, Sukru Nail
dc.contributor.authorKeles, Sevgi
dc.contributor.authorReisli, Ismail
dc.contributor.authorSomer, Ayper
dc.contributor.authorGuven, Ayla
dc.contributor.authorAYAZ, Nuray
dc.contributor.authorAksu, Guzide
dc.contributor.authorCharbonnier, Louis Marie
dc.contributor.authorNain, Ercan
dc.contributor.authorCekic, Sukru
dc.contributor.authorKutukculer, Necil
dc.contributor.authorKilic, Sara S.
dc.contributor.authorYilmaz, Mustafa
dc.contributor.authorKarakoc-Aydiner, Elif
dc.contributor.authorLO, Bernice
dc.contributor.authorOzen, Ahmet
dc.contributor.authorChatila, Talal A.
dc.contributor.authorBaris, Safa
dc.contributor.authorKara, Manolya
dc.contributor.authorKiykim, Ayca
dc.contributor.authorÖĞÜLÜR, İSMAİL
dc.contributor.authorDursun, Esra
dc.contributor.authorDOĞRUEL, DİLEK
dc.contributor.authorKaraca, Neslihan Edeer
dc.contributor.authorÇÖĞÜRLÜ, MÜJDE TUBA
dc.contributor.authorBILIR, Ozlem Arman
dc.contributor.authorCansever, Murat
dc.date.accessioned2021-03-05T20:33:54Z
dc.date.available2021-03-05T20:33:54Z
dc.date.issued2019
dc.identifier.citationKiykim A., ÖĞÜLÜR İ., Dursun E., Charbonnier L. M. , Nain E., Cekic S., DOĞRUEL D., Karaca N. E. , ÇÖĞÜRLÜ M. T. , BILIR O. A. , et al., "Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, cilt.7, ss.2790-2815, 2019
dc.identifier.issn2213-2198
dc.identifier.othervv_1032021
dc.identifier.otherav_d4bf9ce5-4820-40a5-8334-9e1d5ae07645
dc.identifier.urihttp://hdl.handle.net/20.500.12627/140411
dc.identifier.urihttps://doi.org/10.1016/j.jaip.2019.06.011
dc.description.abstractBACKGROUND: LPS-responsive beige-like anchor (LRBA) deficiency presents with susceptibility to infections, autoimmunity, and lymphoproliferation. The long-term efficacy of cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (abatacept) as targeted therapy for its immune dysregulatory features remains to be established.
dc.language.isoeng
dc.subjectTıp
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectİmmünoloji
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectALERJİ
dc.subjectTemel Bilimler
dc.titleAbatacept as a Long-Term Targeted Therapy for LRBA Deficiency
dc.typeMakale
dc.relation.journalJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
dc.contributor.departmentMarmara Üniversitesi , ,
dc.identifier.volume7
dc.identifier.issue8
dc.identifier.startpage2790
dc.identifier.endpage2815
dc.contributor.firstauthorID39148


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster